Harel Insurance Investments & Financial Services Ltd. Buys 7,395 Shares of CVS Health Corporation $CVS

Harel Insurance Investments & Financial Services Ltd. grew its position in CVS Health Corporation (NYSE:CVS) by 2,465.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,695 shares of the pharmacy operator’s stock after purchasing an additional 7,395 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in CVS Health were worth $579,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Avion Wealth grew its stake in CVS Health by 99.0% during the second quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 189 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of CVS Health by 72.1% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 142 shares in the last quarter. Corundum Trust Company INC bought a new stake in CVS Health during the 3rd quarter worth approximately $29,000. Harbor Asset Planning Inc. acquired a new stake in CVS Health during the 2nd quarter valued at $30,000. Finally, Front Row Advisors LLC raised its position in CVS Health by 436.5% in the 2nd quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 371 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Down 3.5%

Shares of NYSE CVS opened at $78.51 on Monday. The company’s 50 day simple moving average is $78.84 and its 200 day simple moving average is $74.34. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. CVS Health Corporation has a fifty-two week low of $51.79 and a fifty-two week high of $85.15. The firm has a market capitalization of $99.66 billion, a P/E ratio of 206.61, a P/E/G ratio of 0.72 and a beta of 0.48.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.24. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The company had revenue of $102.87 billion for the quarter, compared to the consensus estimate of $98.85 billion. During the same quarter in the prior year, the business posted $1.09 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, analysts predict that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd will be paid a $0.665 dividend. The ex-dividend date of this dividend is Thursday, January 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.4%. CVS Health’s dividend payout ratio is 700.00%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CVS. Truist Financial set a $100.00 target price on CVS Health in a research note on Wednesday, December 10th. JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Jefferies Financial Group upped their target price on shares of CVS Health from $92.00 to $98.00 in a research report on Thursday, October 30th. Morgan Stanley increased their price target on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, December 10th. Finally, Piper Sandler restated an “overweight” rating and issued a $101.00 price objective (up previously from $99.00) on shares of CVS Health in a research report on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $94.86.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.